Pediatric Hematology, Oncology and Bone Marrow Transplant

The specific goals of the UW Pediatric Hematology, Oncology and Bone Marrow Transplant program are to provide innovative excellence in the:

1. Delivery of state-of-the-art multi-modality, integrated care, including bone marrow transplant (BMT), aimed at total cure of all pediatric malignancies and optimal treatment of hematological disorders;
2. Laboratory and clinical research devoted to the investigation of recognition and destruction of cancer cells using immunologic and molecular pathways
3. Educating the next generation of laboratory and clinical innovators who will continue to provide leadership and excellence in this field.

To accomplish this, and to improve the outcome of children with malignancies, all members of this program participate in comprehensive, cost effective, state-of-the-art, culturally competent, multidisciplinary care for all childhood cancer and hematology patients, both during and after therapy.

 

A Distinctive Clinical Environment

• The American Family Children’s Hospital opened in 2007 and houses our 16-bed inpatient service, adjacent 22-bed PICU, and includes 4 bone marrow transplant beds and an I-131 MIBG radiotherapy suite.
• American Family Children's Hospital ranked in the top 50 in seven medical specialties in the 2012-13 U.S. News and World Report Best Children's Hospitals Guide, including for Cancer.
• The UW Carbone Cancer Center is the only Comprehensive Cancer Center designated by the National Cancer Institute in Wisconsin.
• Our Production Assistance for Cellular Therapies (PACT) center serves as a resource for optimizing novel cell therapies, such as natural killer cell infusions, for children with refractory cancer, and UW is one of only five PACT centers nationwide designated by the National Heart, Lung and Blood Institute.
• We are one of 27 member centers of the Cancer Immunotherapy Trials Network (CITN) in the US, and have research labs within the UW Pediatric Hematology, Oncology and Bone Marrow Transplant division dedicated toward developing novel immunotherapies for cancer.
• Our division treats approximately 100 new oncology patients and 150 new hematology patients per year.
• The Blood and Marrow Transplant service, which has grown annually, currently manages approximately 10 new transplants (malignant and nonmalignant diseases) per year.
• We are a fully accredited member center of the Children’s Oncology Group, the New Agents for Neuroblastoma Treatment (NANT) consortium, the Pediatric Blood and Marrow Transplant consortium (PBMTC), the Primary Immune Deficiency Treatment Consortium (PIDTC) and a Pediatric Neuro-oncology collaborative group. As a result, our division participates in pediatric phase I, II, and III trials of both traditional cytotoxic chemotherapy and novel immunobiologic anticancer therapies.
• We were named one of seven centers participating in a Pediatric Cancer Dream Team, as awarded by the Stand Up to Cancer Foundation, St. Baldrick's Foundation and the American Association of Cancer Research.

Search for clinical trials available at the UW Carbone Cancer Center